SCHEMBL464726

SCHEMBL464726

Nc1nc2ccc(S(=O)(=O)Cl)cc2s1

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.76
HPGD P15428 2/20 0.76
LMNA P02545 2/20 0.76
HSD17B10 Q99714 2/20 0.76
KDM4E B2RXH2 1/20 0.76
PKM P14618 1/20 0.76
KMT2A Q03164 1/20 0.76
MAPT P10636 3/20 0.59
GFER P55789 2/20 0.59
VDR P11473 1/20 0.59
GPR55 Q9Y2T6 1/20 0.59
CYP2D6 P10635 1/20 0.59
CYP3A4 P08684 4/20 0.58
TSHR P16473 1/20 0.54
TDP1 Q9NUW8 1/20 0.54
SMN1; SMN2 Q16637 3/20 0.53
HTT P42858 2/20 0.53
USP2 O75604 1/20 0.53
CYP2C19 P33261 2/20 0.53
RAB9A P51151 3/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30991708 0.87 ALDH1A1 (0.57) ALDH1A1HPGDLMNAHSD17B10KDM4E
SCHEMBL25213930 0.87 ALDH1A1 (0.57) ALDH1A1HPGDLMNAHSD17B10KDM4E
SCHEMBL8298594 0.86 ALDH1A1 (1.00) ALDH1A1HPGDLMNAHSD17B10KDM4E
SCHEMBL687982 0.85 ALDH1A1 (0.78) ALDH1A1HPGDLMNAHSD17B10KDM4E
SCHEMBL1498187 0.83 ALDH1A1 (0.76) ALDH1A1HPGDLMNAHSD17B10KDM4E
SCHEMBL686784 0.83 ALDH1A1 (0.76) ALDH1A1HPGDLMNAHSD17B10KDM4E
Hydrochloric Acid SCHEMBL27732230 0.82 ALDH1A1 (0.73) ALDH1A1HPGDLMNAHSD17B10KDM4E
SCHEMBL1094028 0.81 KMT2A (0.50) ALDH1A1HPGDLMNAHSD17B10KDM4E
SCHEMBL9722734 0.81 ALDH1A1 (0.71) ALDH1A1HPGDLMNAHSD17B10KDM4E
SCHEMBL9722738 0.80 ALDH1A1 (0.66) ALDH1A1HPGDLMNAHSD17B10KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114025299-B Diaphragm comprising a conductive coating and its use in the manufacture of an acoustic device 常州星启电子科技有限公司 2022-08-02 CN claimed
US-20250115569-A1 SULFONAMIDE COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL CONDITIONS LARIO THERAPEUTICS LTD (GB) 2025-04-10 US disclosed
EP-4436955-A1 SULFONAMIDE COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL CONDITIONS Lario Therapeutics Limited (GB) 2024-10-02 EP disclosed
CN-118317950-A Sulfonamide compounds for the treatment of neurological disorders 拉里奥治疗有限公司 2024-07-09 CN disclosed
WO-2023094830-A1 SULFONAMIDE COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL CONDITIONS LARIO THERAPEUTICS LIMITED (GB) 2023-06-01 WO disclosed
WO-2023094830-A1 SULFONAMIDE COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL CONDITIONS LARIO THERAPEUTICS LIMITED (GB) 2023-06-01 WO disclosed
CN-114025299-B Diaphragm comprising a conductive coating and its use in the manufacture of an acoustic device 常州星启电子科技有限公司 2022-08-02 CN disclosed
CN-114025299-A Diaphragm comprising a conductive coating and its use in the manufacture of an acoustic device 常州星启电子科技有限公司 2022-02-08 CN disclosed
US-8455497-B2 Inhibitors of aspartyl protease VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-06-04 US disclosed
US-8436040-B2 Method of treating conditions involving PPAR-receptors with indole compounds LABORATOIRES FOURNIER S.A. (FR) 2013-05-07 US disclosed
US-20040122000-A1 Inhibitors of aspartyl protease VERTEX PHARMACEUTICALS INCORPORATED. 2004-06-24 US disclosed
US-20040097594-A1 Sulfonamide inhibitors of aspartyl protease HALE MICHAEL ROBIN (US) 2004-05-20 US disclosed
WO-2004014371-A1 BROADSPECTRUM 2-AMINO-BENZOTHIAZOLE SULFONAMIDE HIV PROTEASE INHIBITORS TIBOTEC PHARMACEUTICALS LTD. (IE) 2004-02-19 WO disclosed
US-6613743-B2 Administering to a patient suffering from viral infections a sulfonamides antiviral agents which are aspartyl protease inhibitors VERTEX PHARMACEUTICALS INCORPORATED 2003-09-02 US disclosed
CN-1361765-A Aspartyl protease inhibitors VERTEX PHARMA (US) 2002-07-31 CN disclosed
US-20020049201-A1 Sulfonamide inhibitors of aspartyl protease VERTEX PHARMACEUTICALS INCORPORATED 2002-04-25 US disclosed
EP-1194404-A1 INHIBITORS OF ASPARTYL PROTEASE Vertex Pharmaceuticals Incorporated (US) 2002-04-10 EP disclosed
EP-1086076-A1 SULFONAMIDE INHIBITORS OF ASPARTYL PROTEASE Vertex Pharmaceuticals Incorporated (US) 2001-03-28 EP disclosed
WO-2000076961-A1 INHIBITORS OF ASPARTYL PROTEASE VERTEX PHARMACEUTICALS INCORPORATED (US) 2000-12-21 WO disclosed
WO-1999065870-A2 SULFONAMIDE INHIBITORS OF ASPARTYL PROTEASE VERTEX PHARMACEUTICALS INCORPORATED (US) 1999-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040097594-A1 Sulfonamide inhibitors of aspartyl protease SPINT2, PRSS1, DNPEP ALDH1A1 1841/4885HPGD 2994/4885LMNA 3901/4885
US-20020049201-A1 Sulfonamide inhibitors of aspartyl protease SPINT2, PRSS1, DNPEP ALDH1A1 1841/4885HPGD 2994/4885LMNA 3901/4885
US-20250115569-A1 SULFONAMIDE COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL CONDITIONS CACNA1A, CACNA1E, CACNA1S ALDH1A1 3306/4885HPGD 4398/4885LMNA 2500/4885
US-20040122000-A1 Inhibitors of aspartyl protease SPINT2, DNPEP, PRSS1 ALDH1A1 1604/4885HPGD 2979/4885LMNA 4130/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.